Klaviyo (KVYO) director and 10% owner reports planned stock sales

Rhea-AI Filing Summary

Klaviyo, Inc. insider reports planned stock sales under Rule 10b5-1 plan. A reporting person who is both a director and 10% owner disclosed two sales of Klaviyo Series A common stock on December 17, 2025, executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025.

The filing shows a sale of 34,878 shares at a weighted average price of $30.35 per share through the Hodgkins Trust, leaving 133,624 shares beneficially owned through that trust. It also reports a sale of 82,672 shares at a weighted average price of $30.37 per share through Hodgkins LLC, leaving 525,246 shares beneficially owned through that entity.

Both positions are held indirectly, with the reporting person disclaiming beneficial ownership beyond any pecuniary interest. The prices in each transaction reflect multiple individual trades within disclosed price ranges.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hallen Ed

(Last) (First) (Middle)

C/O KLAVIYO, INC. 125 SUMMER STREET

6TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klaviyo, Inc. [ KVYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Series A Common Stock	12/17/2025		S(1)		34,878	D	$30.35(2)	133,624	I	By Hodgkins Trust(3)
Series A Common Stock	12/17/2025		S(1)		82,672	D	$30.37(4)	525,246	I	By Hodgkins LLC(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.71 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.695 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.

Remarks:

	/s/ Landon Edmond, Attorney-in-Fact	12/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Klaviyo (KVYO) report in this Form 4?

The filing reports that a director and 10% owner of Klaviyo, Inc. sold Series A common stock on December 17, 2025 in two separate transactions, both disclosed as open-market sales.

How many Klaviyo (KVYO) shares were sold in the reported transactions?

The reporting person sold 34,878 shares through the Hodgkins Trust and 82,672 shares through Hodgkins LLC, as shown in Table I of the filing.

What prices were received for the Klaviyo (KVYO) shares sold?

The filing lists a weighted average price of $30.35 per share for the 34,878 shares and $30.37 per share for the 82,672 shares. Each weighted price reflects multiple trades within stated price ranges.

How many Klaviyo (KVYO) shares does the insider report owning after these sales?

After the transactions, the insider reports 133,624 shares of Series A common stock beneficially owned through the Hodgkins Trust and 525,246 shares beneficially owned through Hodgkins LLC.

Were the Klaviyo (KVYO) insider sales made under a Rule 10b5-1 plan?

Yes. The explanation of responses states that these transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.

How does the insider hold the reported Klaviyo (KVYO) shares?

The filing notes that shares are held indirectly through the Hodgkins Trust and Hodgkins LLC, with the reporting person disclaiming beneficial ownership except to the extent of any pecuniary interest.